RKL Wealth Management LLC Invests $237,000 in Eli Lilly and Company (LLY)
RKL Wealth Management LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,755 shares of the company’s stock, valued at approximately $237,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Airain ltd purchased a new stake in Eli Lilly and in the 2nd quarter worth approximately $567,000. Buckingham Asset Management LLC grew its holdings in Eli Lilly and by 21.3% during the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock valued at $266,000 after buying an additional 568 shares in the last quarter. BSW Wealth Partners grew its holdings in Eli Lilly and by 0.6% during the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock valued at $393,000 after buying an additional 27 shares in the last quarter. Sumitomo Life Insurance Co. grew its holdings in Eli Lilly and by 4.4% during the 2nd quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after buying an additional 1,370 shares in the last quarter. Finally, Mirador Capital Partners LP grew its holdings in Eli Lilly and by 5.3% during the 2nd quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock valued at $1,011,000 after buying an additional 619 shares in the last quarter. 76.30% of the stock is owned by institutional investors.
A number of equities research analysts have issued reports on LLY shares. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price objective on shares of Eli Lilly and in a report on Monday, September 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Cowen reaffirmed a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Finally, Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a report on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $90.25.
Eli Lilly and Company (NYSE LLY) opened at $85.74 on Thursday. Eli Lilly and Company has a fifty-two week low of $72.68 and a fifty-two week high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The firm has a market cap of $95,475.95, a price-to-earnings ratio of 21.20, a P/E/G ratio of 1.79 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period last year, the firm posted $0.88 earnings per share. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. research analysts predict that Eli Lilly and Company will post 4.22 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.62%. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.